BEIJING, May 06, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to initiate a clinical trial of its novel CDH17 targeted ADC, ICP-B208. CDH17 is a calcium-dependent cell adhesion protein that plays a key role in tumor cell proliferation, migration, and metastasis. Its tumor-restricted expression and functional role in cancer biology make CDH17 an attractive and differentiated target for ADC therapy, which can be developed for the treatment of gastrointestinal cancers, including colorectal, gastric, pancreatic ductal adenocarcinoma, and biliary...

JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company’s Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employment with the Company. The awards were granted as a material inducement to the employee’s acceptance of employment and were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were granted pursuant to SCYNEXIS’ 2015 Inducement Award Plan, as amended, which was adopted by the Company’s Board of Directors in March 2015 under...

CALGARY, Alberta, May 06, 2026 (GLOBE NEWSWIRE) — Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”), announces that at its Annual and Special Meeting of Shareholders (the “Meeting”) held virtually on May 6, 2026, Enerflex’s shareholders approved the election of all 10 nominee directors presented in the Company’s Management Information Circular dated March 20, 2026. The shares represented at the Meeting voting on individual nominee directors were as follows:  Approval AgainstDirector Votes For Percentage Votes Against PercentageFernando R. Assing 86,602,468 97.65% 2,088,077 2.35%Benjamin Cherniavsky 86,622,946 97.67% 2,067,599 2.33%Joanne Cox 86,155,032 97.14% 2,535,513 2.86%Céline B. Gerson 86,706,678 97.76% 1,983,867 2.24%James C. Gouin 88,278,871 99.54% 411,674 0.46%Mona...

TORONTO, May 06, 2026 (GLOBE NEWSWIRE) — Altus Group Limited (ʺAltus Group” or “the Company”) (TSX: AIF), a leading provider of commercial real estate (“CRE”) intelligence, released today final voting results from its annual general and special meeting of shareholders (the “Meeting”) held virtually earlier today. A total of 30,320,370 common shares were represented at the Meeting, representing 76.07% of the 39,857,533 Common Shares of the Company as at the record date on March 25, 2026. Each of the nominees proposed for election as a director as listed in the Company’s Management Information Circular dated March 25, 2026, was elected by a majority of votes to serve until the next annual meeting or until a successor is elected or appointed, as detailed below:Name of Nominee Votes For % Votes Withheld % Will Brennan 29,230,949 98.54% 432,992 1.46% Angela...